Core Viewpoint - The company, Maide Medical, has released its 2025 annual performance forecast, indicating significant revenue growth and a return to profitability, primarily driven by increased sales in smart medical equipment [1]. Group 1: Financial Performance - As of January 26, 2026, Maide Medical's stock closed at 16.26 yuan, down 1.57% from the previous trading day, with a total market capitalization of 2.703 billion yuan [1]. - The company expects to achieve approximately 447.50 million yuan in revenue for 2025, representing a year-on-year growth of 62.81% [1]. - The net profit attributable to the parent company is projected to be around 66.52 million yuan, marking a return to profitability [1]. - The net profit after deducting non-recurring gains and losses is estimated to be about 54.64 million yuan [1]. Group 2: Revenue Drivers - The significant growth in revenue is primarily attributed to a substantial increase in sales of smart medical equipment, particularly in the drug and device combination sector [1].

截至2026年1月26日收盘，迈得医疗(688310)报收于16.26元，下跌1.57%，换手率1.94%，成交量3.23万 手，成交额5225.49万元。 资金流向 迈得医疗工业设备股份有限公司2025年年度业绩预告 经财务部门初步测算，预计迈得医疗2025年年度实现营业收入44,749.77万元左右，同比增长62.81%； 归属于母公司所有者的净利润为6,652.13万元左右，实现扭亏为盈；扣除非经常性损益后的净利润为 5,463.95万元左右。业绩增长主要得益于营业收入大幅提升，尤其是药械组合类智能装备收入显著增 长。本期业绩预告未经注册会计师审计。 1月26日主力资金净流出115.69万元；游资资金净流出11.45万元；散户资金净流入127.14万元。 业绩披露要点 业绩预告 迈得医疗发布业绩预告，预计2025年全年营业收入4.47亿元。迈得医疗发布业绩预告，预计2025年全年 扣非后净利润盈利约5463.95万元。迈得医疗发布业绩预告，预计2025年全年归属净利润盈利约6652.13 万元。 公司公告汇总 当日关注点 交易信息汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备31010 ...

中证智能财讯迈得医疗（688310）1月26日晚间披露2025年度业绩预告，预计2025年归母净利润6652.13万元，上年同期亏损1998.12万元；扣非净利润预计 5463.95万元，上年同期亏损2628.09万元。以1月26日收盘价计算，迈得医疗目前市盈率（TTM）约为40.63倍，市净率（LF）约3.35倍，市销率（TTM）约 9.66倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况（倍） 200 @ 20 100 300 50 47624 40919 To83 29877 32x43 29.54 224 0 -50 -100 -150 2022-06-30 2021-12-37 2021-06-30 ' 2020-12-37 2022-12-37 <3-12-37 3-06-30 2n. -○- 公司 -○- 行业均值 100 ହ 90 80 70 63 69 60 50 (8 40 30 2 20 15086 15 10 AR 0 2027-12-37 | 2022-72-37 1 2020-12-37 1 2021-06-30 ' 023-12-37 ...

Group 1 - Evert plans to acquire equity in Shengpu Co., with stock suspension starting January 27, 2026, expected to last no more than 10 trading days [5] - Haike New Source signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of electrolyte solvent annually for three years [5] - Sanxiang Bio has developed a CE-certified Nipah virus nucleic acid testing kit and a domestic research version, responding to the Nipah virus outbreak in India [9][10] Group 2 - Sangfor Health expects a Q4 net profit of approximately 2.5 billion yuan, a 1097% increase from the previous quarter, driven by a significant payment from Pfizer for the 707 project [2] - Puran Co. anticipates a Q4 net profit of about 1.46 billion yuan, a 696% increase from Q3, despite an annual decrease of approximately 29.89% [3][4] - Chip Source Micro expects a net profit of 52 million to 76 million yuan for 2025, a decrease of 62.53% to 74.36% year-on-year due to increased costs and reduced other income [6] Group 3 - Maide Medical forecasts a net profit of approximately 66.5 million yuan for 2025, marking a turnaround from losses in the previous year [7] - Ruixin Micro expects a net profit of 1.023 billion to 1.103 billion yuan for 2025, representing a growth of 71.97% to 85.42% year-on-year [8] - Qingda Environmental anticipates a net profit of 165 million to 190 million yuan for 2025, an increase of 77.47% to 104.36% year-on-year [10] Group 4 - Jiangxun Technology expects a net profit increase of approximately 86.44% for 2025, reaching around 156 million yuan [11] - Micron Bio anticipates a net profit of approximately 53.5 million yuan for 2025, achieving profitability after previous losses [11] - Blue Special Optics forecasts a net profit of 375 million to 400 million yuan for 2025, a growth of 70.04% to 81.38% year-on-year [13]

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, projecting approximately 66.52 million yuan, driven by substantial growth in overall operating revenue and successful product delivery [1] Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of approximately 66.52 million yuan for the year 2025 [1] - The increase in revenue is attributed to the orderly implementation of production plans and a focus on technological innovation and process iteration [1] - The blood purification and drug-device combination intelligent equipment business is performing well, particularly due to strong demand growth in the terminal market for medical consumables [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 225 million yuan, a year-on-year increase of 2.31% [2] - The net profit attributable to shareholders for the same period was 8.84 million yuan, reflecting a year-on-year increase of 15.82% [2] - In Q3 2025 alone, the company reported a main revenue of 83.64 million yuan, a significant year-on-year increase of 54.38% [2] - The net profit for Q3 2025 was 2.79 million yuan, showing a remarkable year-on-year increase of 224.07% [2] - The company reported a debt ratio of 29.86% and a gross profit margin of 40.19% [2]

证券之星消息，迈得医疗发布业绩预告，预计2025年全年扣非后净利润盈利约5463.95万元。 公告中解释本次业绩变动的原因为： 迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 2025年度,公司整体营业收入实现大幅增长,主要系公司统筹推进生产计划有序落地,保障了产品有效交付, 并且坚持技术创新与工艺迭代双轮驱动,持续强化产品竞争力与市场影响力,血液净化类和药械组合类智 能装备业务发展良好,尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态势,对应 ...

迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公告中解释本次业绩变动的原因为： 2025年度,公司整体营业收入实现大幅增长,主要系公司统筹推进生产计划有序落地,保障了产品有效交付, 并且坚持技术创新与工艺迭代双轮驱动,持续强化产品竞争力与市场影响力,血液净化类和药械组合类智 能装备业务发展良好,尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态势,对应药械 组合类智能装备市场需求前景乐观,公司重点围绕药械组合类智能装备展开新产品研发和市场开拓, ...

迈得医疗(688310.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润与上年同期(法 定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元左右。 ...

智通财经APP讯，迈得医疗(688310.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润与上年同期(法定披露数据)相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元 左右。 ...

（记者 曾健辉） 每经AI快讯，迈得医疗1月26日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 与上年同期相比，将实现扭亏为盈，实现归属于母公司所有者的净利润6652.13万元左右。业绩变动主 要原因是，2025年度，公司整体营业收入实现大幅增长，主要系公司统筹推进生产计划有序落地，保障 了产品有效交付，并且坚持技术创新与工艺迭代双轮驱动，持续强化产品竞争力与市场影响力，血液净 化类和药械组合类智能装备业务发展良好，尤其得益于药械组合类医用耗材在终端市场展现出良好的需 求增长态势，对应药械组合类智能装备市场需求前景乐观，公司重点围绕药械组合类智能装备展开新产 品研发和市场开拓，本期药械组合类智能装备收入实现较大增长。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...